Search Results - "A. De Giglio"

Characterization of the geographical origin of Italian red wines based on traditional and nuclear magnetic resonance spectrometric determinations by Brescia, M.A, Caldarola, V, De Giglio, A, Benedetti, D, Fanizzi, F.P, Sacco, A

“…Chemical characterization of Italian red wines from different geographical locations in the Apulia, region of southern Italy, have been performed by means of…”
Get full text

A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management by C. Casadio, L. Galvani, A. De Giglio, C. Casadei, M.L. Tardio, B. Melotti, F. Sperandi, F. Gelsomino, F. Comito

“…Background: Immune checkpoint inhibitors (ICIs) have become the standard of care in several solid tumours. Thus the action of ICIs may lead to the development…”
Get full text

Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review by Nigro, Maria Concetta, Marchese, Paola Valeria, Deiana, Chiara, Casadio, Chiara, Galvani, Linda, Di Federico, Alessandro, De Giglio, Andrea

“…Precision medicine has revolutionized the therapeutic management of cancer patients with a major impact on non-small cell lung cancer (NSCLC), particularly…”
Get full text

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes by Cortellini, A., Leonetti, A., Catino, A., Pizzutillo, P., Ricciuti, B., De Giglio, A., Chiari, R., Bordi, P., Santini, D., Giusti, R., De Tursi, M., Brocco, D., Zoratto, F., Rastelli, F., Citarella, F., Russano, M., Filetti, M., Marchetti, P., Berardi, R., Torniai, M., Cortinovis, D., Sala, E., Maggioni, C., Follador, A., Macerelli, M., Nigro, O., Tuzi, A., Iacono, D., Migliorino, M. R., Banna, G., Porzio, G., Cannita, K., Ferrara, M. G., Bria, E., Galetta, D., Ficorella, C., Tiseo, M.

“…Background In most cases, T790M EGFR -positive NSCLC patients receiving osimertinib developed “non-drugable” progression, as the patients with common EGFR…”
Get full text

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer by Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.

“…To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated with first-line…”
Get full text

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer by Ricciuti, B., Brambilla, M., Cortellini, A., De Giglio, A., Ficorella, C., Sidoni, A., Bellezza, G., Crinò, L., Ludovini, V., Baglivo, S., Metro, G., Chiari, R.

“…Purpose KRAS mutation has been associated with enhanced dependency on the folate metabolism in preclinical studies. However, whether KRAS mutation correlates…”
Get full text

Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels by Ricciuti, B., Chiari, R., Tofanetti, F.R., De Giglio, A., Porreca, R., Brambilla, M., Sperduti, I., Bellezza, G., Mencaroni, C., Siggillino, A., Zicari, D., Baldi, A., Ludovini, V., Metro, G.

Get full text

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] by Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.

Get full text

An unusual case of occupational asthma in a part time magician. He has got an allergy surprise from his top hat by LICCARDI, G, BILLERI, L, FOGLIA, M, SAPIO, C, DE GIGLIO, M. A. R, D'AMATO, G

“…In this report we describe a case of respiratory allergy induced by an unusual occupational exposure to rabbit. The patient worked as a part-time magician in…”
Get full text

1477P STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status by De Giglio, A., de Biase, D., Di Federico, A., Maloberti, T., Casadio, C., Gruppioni, E., Altimari, A., Melotti, B., Sperandi, F., Gelsomino, F., Ardizzoni, A.

Get full text

25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) by Riudavets Melia, M., Auclin, E., Aboubakar, F., Ponce Aix, S., Dal Maso, A., Bluthgen, V., Mielgo, X., Mussat, E., Reyes, R., Benítez, J., Lupinacci, L., Duchemann, B., de Giglio, A., Bautista, J., Audigier-Valette, C., Scheffler, M., Campayo, M., Besse, B., Planchard, D., Mezquita, L.

Get full text

Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated by De Giglio, A., Mezquita, L., Auclin, E., Blanc-Durand, F., El-Amarti, L., Caramella, C., Bernal, G. Martinez, Hendriks, L., Ferrara, R., Naltet, C., Lavaud, P., Gazzah, A., Adam, J., Planchard, D., Chaput, N., Besse, B.

Get full text

Characterisation of mineral waters by pattern recognition methods by Caselli, Maurizio, De Giglio, Angelo, Mangone, Annarosa, Traini, Angela

“…Eighty‐three samples of mineral water from four different wells in the same district were analysed for 23 parameters. Nineteen parameters were chosen for…”
Get full text

Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study by Nigro, O., Cortellini, A., Giusti, R., Marchetti, P., De Galitiis, F., Di Pietro, F.R., Bersanelli, M., Lazzarin, A., Galetta, D., Pizzutillo, P., Santini, D., Torniai, M., De Giglio, A., Russo, A., Silva, R.R., Bolzacchini, E., Natoli, C., Rijavec, E., Vallini, I., Pinotti, G.

Get full text

Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection by Costanzo, Michele, De Giglio, Maria Anna Rachele, Roviello, Giovanni Nicola

“…The aim of this review article is to summarize the knowledge available to date on prophylaxis achievements in the frame of the fight against Coronaviruses…”
Get more information

An interference-free first generation alcohol biosensor based on a gold electrode modified by an overoxidised non-conducting polypyrrole film by Carelli, Donatella, Centonze, Diego, De Giglio, Angelo, Quinto, Maurizio, Zambonin, Pier Giorgio

“…An interference-free first generation alcohol biosensor based on alcohol oxidase immobilized, by glutaraldehyde co-crosslinking with bovine serum albumin, on a…”
Get full text

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: ESMO Open Volume 6, Issue 2, April 2021, 100078 by Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.

Get full text